Literature DB >> 23710755

Dot immunogold filtration assay (DIGFA) for the rapid detection of specific antibodies against the rat lungworm Angiostrongylus cantonensis (Nematoda: Metastrongyloidea) using purified 31-kDa antigen.

P Eamsobhana1, X X Gan2, A Ma2, Y Wang2, D Wanachiwanawin1, H S Yong3.   

Abstract

A rapid dot immunogold filtration assay (DIGFA) was adopted for specific immunodiagnosis of human cerebral angiostrongyliasis, using purified 31-kDa glycoprotein specific to Angiostrongylus cantonensis as diagnostic antigen and protein A colloidal gold conjugate as antigen-antibody detector. A total of 59 serum samples were assayed - 11 samples from clinically diagnosed patients with detectable A. cantonensis-specific antibody in immunoblotting; 23 samples from patients with other related parasitic diseases, i.e. gnathostomiasis (n= 8), cysticercosis (n= 5), toxocariasis (n= 2), filariasis (n= 4), paragonimiasis (n= 2) and malaria (n= 2); and 25 samples from normal healthy subjects. The sensitivity and specificity of DIGFA to detect anti-A. cantonensis specific antibodies in serologically confirmed angiostrongyliasis cases, were both 100%. No positive DIGFA was observed in cases with other parasitic diseases, and the healthy control subjects. The 3-min DIGFA is as sensitive and specific as the 3-h immunoblot test in angiostrongyliasis confirmed cases that revealed a 31-kDa reactive band. The gold-based DIGFA is more rapid and easier to perform than the traditional enzyme-linked immunosorbent assay (ELISA). The test utilizing purified A. cantonensis antigen is reliable and reproducible for specific immunodiagnosis of human infection with A. cantonensis - thus can be applied as an additional routine test for clinical diagnostic support. Large-scale sero-epidemiological studies in endemic communities in north-east Thailand are under way to evaluate its usefulness under field conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23710755     DOI: 10.1017/S0022149X13000321

Source DB:  PubMed          Journal:  J Helminthol        ISSN: 0022-149X            Impact factor:   2.170


  6 in total

1.  Angiostrongylus cantonensis an Atypical Presenilin: Epitope Mapping, Characterization, and Development of an ELISA Peptide Assay for Specific Diagnostic of Angiostrongyliasis.

Authors:  Salvatore G De-Simone; Paloma Napoleão-Pêgo; Priscila S Gonçalves; Guilherme C Lechuga; Arnaldo Mandonado; Carlos Graeff-Teixeira; David W Provance
Journal:  Membranes (Basel)       Date:  2022-01-19

2.  Development of Lateral Flow Immunoassay for Antigen Detection in Human Angiostrongylus cantonensis Infection.

Authors:  Mu-Xin Chen; Jia-Xu Chen; Shao-Hong Chen; Da-Na Huang; Lin Ai; Ren-Li Zhang
Journal:  Korean J Parasitol       Date:  2016-06-30       Impact factor: 1.341

Review 3.  Eosinophilic meningitis caused by Angiostrongylus cantonensis: an emergent disease in Brazil.

Authors:  Alessandra Loureiro Morassutti; Silvana Carvalho Thiengo; Monica Fernandez; Kittisak Sawanyawisuth; Carlos Graeff-Teixeira
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-07       Impact factor: 2.743

4.  Autochthonous Case of Eosinophilic Meningitis Caused by Angiostrongylus cantonensis, France, 2016.

Authors:  Yann Nguyen; Benjamin Rossi; Nicolas Argy; Catherine Baker; Beatrice Nickel; Hanspeter Marti; Virginie Zarrouk; Sandrine Houzé; Bruno Fantin; Agnès Lefort
Journal:  Emerg Infect Dis       Date:  2017-06       Impact factor: 6.883

5.  Angiostrongylus costaricensis infection in Martinique, Lesser Antilles, from 2000 to 2017.

Authors:  Céline Dard; Duc Nguyen; Charline Miossec; Katia de Meuron; Dorothée Harrois; Loïc Epelboin; André Cabié; Nicole Desbois-Nogard
Journal:  Parasite       Date:  2018-04-10       Impact factor: 3.000

6.  First cases of Angiostrongylus cantonensis infection reported in Martinique, 2002-2017.

Authors:  Céline Dard; Eve Tessier; Duc Nguyen; Loïc Epelboin; Dorothée Harrois; Christopher Swale; André Cabié; Katia de Meuron; Charline Miossec; Nicole Desbois-Nogard
Journal:  Parasite       Date:  2020-05-12       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.